Milestone Pharma plans to resubmit NDA for etripamil in 2Q2024 after FDA Type A meeting

Milestone Pharmaceuticals Inc.

FDA indicated that timing of adverse events had minimal impact on overall etripamil safety profile.
No additional clinical efficacy or safety trials required before NDA resubmission; standard review expected.
NDA resubmission for paroxysmal supraventricular tachycardia (PSVT) planned for 2Q2024.
Cash conservation measures extend operating runway into mid-2025, covering expected PDUFA date.
Upon FDA approval, Milestone would receive a $75M payment under an existing royalty agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.